Nalepa I, Vetulani J
Institute of Pharmacology, Polish Academy of Sciences, Kraków.
J Neurochem. 1993 Jun;60(6):2029-35. doi: 10.1111/j.1471-4159.1993.tb03487.x.
The aim of this study was to evaluate the effect of citalopram, a second generation antidepressant agent producing no beta-down-regulation, on the receptors and second messenger systems related to noradrenergic transmission in the cerebral cortex of the rat. We confirmed that citalopram does not bind to alpha 1-, alpha 2-, and beta 1-adrenoceptors, but we found that it attenuates the inhibitory action of the protein kinase C activator, 12-O-tetradecanoylphorbol 13-acetate, on the noradrenergic response from alpha 1-adrenoceptor. In contrast to most antidepressants, chronic treatment with citalopram does not produce beta-down-regulation, but increases the responses to noradrenaline from beta-adrenoceptors without increasing the beta 1-adrenoceptor density. Chronic treatment with citalopram also increases the maximal response from alpha 1-adrenoceptor. The results indicate that beta-down-regulation is not a necessary characteristic of an efficient antidepressant drug.
本研究的目的是评估西酞普兰(一种不会引起β-下调的第二代抗抑郁药)对大鼠大脑皮质中与去甲肾上腺素能传递相关的受体和第二信使系统的影响。我们证实西酞普兰不与α1、α2和β1肾上腺素能受体结合,但我们发现它能减弱蛋白激酶C激活剂12-O-十四酰佛波醇-13-乙酸酯对α1肾上腺素能受体去甲肾上腺素能反应的抑制作用。与大多数抗抑郁药不同,长期使用西酞普兰不会引起β-下调,但会增加β肾上腺素能受体对去甲肾上腺素的反应,而不会增加β1肾上腺素能受体的密度。长期使用西酞普兰还会增加α1肾上腺素能受体的最大反应。结果表明,β-下调并非高效抗抑郁药的必要特征。